EAS Consulting Group is pleased to announce the expansion of our service offerings to include Biologics and Biosimilars regulatory and quality consulting.

As these products continue to play an increasingly important role in the life sciences industry, organizations face complex challenges related to manufacturing, quality systems, and evolving regulatory expectations. EAS supports clients navigating these challenges with practical, risk-based solutions aligned with FDA requirements.

Our Biologics and Biosimilars services include:

• Quality system development and optimization (QMS)
• cGMP compliance and manufacturing support
• FDA inspection readiness and mock audits
• 483 response and remediation support
• Regulatory strategy and submission support (IND/BLA)

EAS brings together experienced consultants with deep expertise across biologicsand biosimilars to support companies at all stages, from development through commercial manufacturing.

If you would like to learn more about our Biologics and Biosimilars capabilities or discuss a specific need, please contact us.